Keywords
How to Cite
Abstract
We have conducted a pilot study of repeated tumor biopsy followed by molecular testing in order to facilitate treatment correction in patients with advanced non-small cell lung cancer progressing on their current therapy. Repeated tumor biopsy was showed to be feasible, well tolerated and highly informative. Use of molecular-matched therapy was associated with significant increase in overall survival in this difficult-to-treat group of cancer patients.References
Аллахвердиев А. К., Лактионов К. К., Полоцкий Б. Е., Давыдов М. И. Современные возможности видеоторакоскопии в практике торакальной онкологии // Вестник Московского онкологического общества. - 2009. - Т. 5. - № 6-8 (559). - С. 2-4
Давыдов М.И., Аксель Е.М. Заболеваемость злокачественными новообразованиями населения России и стран СНГ в 2012 г. Статистика злокачественных новообразований в России и странах СНГ в 2012 г. / Под ред. Давыдова М. И., Аксель Е. М. - М., 2014. - 226 с.
Каприн А. Д., Старинский В. В., Петрова Г. В. Состояние онкологической помощи населению России в 2015 году. - М., 2016. - 236 с.
Bosc C., Ferretti G. R., Cadranel J. et al. Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC // Target Oncol. - 2015. -Vol. 10 (2). - P 247-53. - DOI: 10.1007/s11523-014-0332-y
Du L., Herbst R. S., Morgensztern D. Immunotherapy in lung cancer // Hematol. Oncol. Clin. North Am. -2017. - Vol. 31 (1). - P. 131-141. - 10.1016/j. hoc.2016.08.004. DOI: 10.1016/j.hoc.2016.08.004
IASLC/CAP/AMP Molecular Testing Guideline for Selection of Lung Cancer Patients - Revision 2016 // https://www.iaslc.org/sites/default/files/wysiwyg-assets/5-20160616capiaslcamplungguideline-2016draftrecommendations_ocpfinal.pdf.
Langer C.J., Mok T, Postmus PE. Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer // Cancer Treat. Rev. - 2013. - Vol. 39 (3). - P 252-60. - 10.1016/j. ctrv.2012.05.003. DOI: 10.1016/j.ctrv.2012.05.003
Levy M.A., Lovly C.M., Pao W. Translating genomic information into clinical medicine: lung cancer as a paradigm // Genome Res. - 2012. - Vol. 22 (11). - P 2101-2108. - DOI: 10.1101/gr.131128.111
Meador C.B., Micheel C.M., Levy M.A. et al. Beyond histology: translating tumor genotypes into clinically effective targeted therapies // Clin Cancer Res. - 2014. - Vol. 20 (9). - P 2264-2275. - CCR-13-1591. DOI: 10.1158/1078-0432
NCCN Guidelines with Evidence Blocks: Non-Small Cell Lung Cancer Version 3.2017 // http://www.nccn.org/ professionals/physician_gls/pdf/nscl_blocks.pdf.
Pao W., Miller V., Zakowski M. et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib // Proc. Natl. Acad. Sci. U S A. -2004. - Vol. 101 (36). - P. 13306-13311.
Sacher A.G., Paweletz C., Dahlberg S.E. et al. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer // JAMA Oncol. - 2016. - Vol.2 (8). - P. 1014-1022. - DOI: 10.1001/jamaoncol.2016.0173
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2017